After decades of scientific setbacks and hundreds of failed clinical trials, the field of Alzheimer's drug development has transformed. This shift is highlighted by the approval of the first disease-modifying therapies, such as aducanumab (Aduhelm) in 2021, and later lecanemab (Leqembi) in July 2023, and donanemab (Kisunla) in July 2024. These drugs, developed by companies like Eisai, Biogen, and Eli Lilly, target amyloid plaques in the brain and have shown the ability to slow cognitive decline, a feat previously unachieved by approved Alzheimer's medicines.

The success of these new anti-amyloid drugs, particularly Eisai Co.'s treatment, has quieted a long-standing dispute among scientists regarding the amyloid hypothesis—the theory that abnormal accumulation of amyloid protein is a central trigger for Alzheimer's. Proponents of this theory are now declaring victory, with some former skeptics changing their stance. This progress has far-reaching consequences, including implications for Medicare coverage of these new treatments.

The Alzheimer’s drug pipeline in 2026 is the largest in history, with 192 active clinical trials evaluating 158 novel agents, an increase from 182 trials and 138 drugs in 2025. Disease-targeting therapies constitute 73% of these agents, with cognition-enhancing symptomatic treatments at 18% and neuropsychiatric symptom treatments at 10%. The year 2026 is anticipated to be one of the most active for clinical news in the field, with eight Phase 3 trial completions expected to influence future development directions. The major scientific meeting, AAIC in July, is set to be particularly consequential.

Improvements in delivery systems and diagnostic pipelines are also accelerating. The field is no longer characterized by accumulating failures but by accumulating evidence. For instance, lecanemab, the first amyloid-targeting antibody to receive traditional FDA approval, slowed cognitive decline by 27% at 18 months in the Phase 3 CLARITY AD trial. Additionally, a tau-directed therapy has recently yielded its first randomized clinical signal, further diversifying the approach to treatment.